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ABSTRACT
Introduction: PF-06438179, a potential
biosimilar to Remicade (infliximab, Janssen
Biotech, Inc.), is a chimeric mouse–human
monoclonal antibody targeting human tumor
necrosis factor alpha (TNF).
Methods: Analytical (small subset reported
here) and nonclinical studies compared the
structural, functional, and in vivo nonclinical
similarity of PF-06438179 with Remicade
sourced from the United States (infliximab-US)
and/or European Union (infliximab-EU).
Results: The peptide map profiles were
superimposable, and peptide masses were the
same, indicating identical amino acid
sequences. Data on post-translational
modifications, biochemical properties, and
biological function provided strong support for
analytical similarity. Administration of a single
intravenous (IV) dose (10 or 50 mg/kg) of
PF-06438179 or infliximab-EU to male rats was
well tolerated. There were no test article-related
clinical signs or effects on body weight or food
consumption. Systemic exposures [maximum
drug concentration (Cmax) and area under the
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concentration–time curve (AUC)] in rats
administered PF-06438179 or infliximab-EU
were similar, with mean exposure ratio of
PF-06438179 relative to infliximab-EU ranging
from 0.88 to 1.16. No rats developed anti-drug
antibodies. A 2-week IV toxicity study was
conducted with once-weekly administration of
10 or 50 mg/kg of PF-06438179 to male and
female rats. PF-06438179-related hyperplasia of
sinusoidal cells occurred in the liver in rats
administered 50 mg/kg, but was not adverse
based on its minimal to mild severity. The
no-observed adverse-effect level for
PF-06438179 was 50 mg/kg. At this dose, Cmax
was 1360 lg/mL and AUC at 168 h was
115,000 lg h/mL on day 8.
Conclusions: The analytical and nonclinical
studies have supported advancement of
PF-06438179 into global comparative clinical
trials.
Funding: Pfizer Inc.





Biosimilars are biopharmaceuticals that are
approved by a regulatory agency and are highly
similar to an approvedmarketed biologic product
[1–3]. There is strong interest throughout the
world in developing biosimilars to many
currently marketed biopharmaceuticals, with
the hope of reduced costs for medical care
coupled with increased accessibility to these
medicines.
Many countries, including those in the
European Union (EU) and the United States
(US), have created abbreviated approval
pathways for biosimilars (compared with the
requirements for innovative molecules) that
require a comparison of the proposed
biosimilar with the approved product,
generally termed the reference product, to
demonstrate biosimilarity. The EU defines the
reference product as the product that has been
granted marketing authorization in the EU [1].
In a similar manner, the US Biologics Price
Competition and Innovation Act defines the
reference product as the US Food and Drug
Administration (FDA)-licensed product [2].
Under certain circumstances, both the
European Medicines Agency (EMA) and FDA
allow the use of data derived from human or
animal studies comparing a proposed biosimilar
to a reference product licensed in another
region that has scientific and regulatory
standards compatible with the International
Conference on Harmonization [2, 4]. From a
practical standpoint, this allows the possibility
of conducting nonclinical in vivo studies with
material from the EU or US to support global
clinical trials. However, at the time of designing
the nonclinical package in support of the
development of PF-06438179, EMA guidance
stipulated the use of the EU reference product,
and hence, for the in vivo nonclinical studies,
the EU reference product was employed as a
comparator. Both regions suggest that
biosimilar development should follow a
stepwise approach, with a greater emphasis on
in vitro assays, followed by generally limited or
possibly no nonclinical in vivo studies prior to
initiation of clinical trials in humans.
Remicade (Infliximab; Janssen Biotech, Inc.
Horsham, PA, USA) is a chimeric human–mouse
monoclonal antibody (mAb) approved
throughout much of the world for the
treatment of a variety of inflammatory
conditions, including Crohn’s disease,
pediatric Crohn’s disease, ulcerative colitis,
pediatric ulcerative colitis, rheumatoid
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arthritis, ankylosing spondylitis, psoriatic
arthritis, and plaque psoriasis [5]. The Fc
region of infliximab is human, while the Fv
region with the complementarity determining
region (CDR) that binds human tumor necrosis
factor alpha (TNF) is derived from the mouse.
Infliximab binds soluble and transmembrane
human TNF and blocks its interaction with p55
and p75 cell surface TNF receptors, thereby
neutralizing the proinflammatory effects of TNF
[6]. A number of nonclinical in vivo studies
were conducted during the development of
infliximab. These included single- and
repeat-dose (up to five doses) studies in
chimpanzees, single- and repeat-dose (up to
seven doses) studies in rats, and a local
tolerance study in rabbits [7]. Nonclinical
toxicity studies were conducted primarily in
chimpanzees because infliximab neutralizes
human and chimpanzee TNF with similar
potency. Infliximab does not have activity
against mouse, rat, rabbit, pig, cotton top
tamarin, marmoset (species not identified),
pigtail macaque, rhesus monkey, cynomolgus
monkey, or baboon TNF [7]. Although weak
activity against dog TNF was observed (0.01% of
potency for human or chimpanzee TNF),
nonclinical testing of infliximab in this species
was discontinued because immediate dermal
hypersensitivity (urticaria and angioedema) was
observed with the initial intravenous (IV)
infusion [7]. In rats, minimal and reversible
hepatic changes (Kupffer cell and hepatocellular
hyperplasia) and slight reductions in
erythrocyte counts, hemoglobin levels, and
hematocrit values were observed after single or
repeat daily doses at C10 mg/kg/day, but these
findings were not considered relevant to
humans, because they were considered to be
related to the response of a normal rat
reticuloendothelial system to large doses of
chimeric (human–mouse) antibody, a foreign
protein to this test animal [8]. Infliximab was
well tolerated in chimpanzees, rabbits, and rats.
Additional studies were conducted in mice
using a surrogate anti-mouse TNF mAb that
was reported to have similar pharmacodynamic
and pharmacokinetic properties as infliximab
[7]. No adverse infliximab surrogate-related
findings were observed in 6-month repeat-dose
or developmental and reproductive toxicity
studies in mice using the surrogate anti-mouse
TNF mAb up to 40 mg/kg [7].
PF-06438179 is an anti-TNF mAb currently
under development as a potential biosimilar to
Remicade. Consistent with current regulatory
authority guidelines [1–3], a stepwise approach
was used during development, whereby
PF-06438179 was first evaluated for structural
and functional similarity to the reference
product in vitro. These analytical studies of
PF-06438179 were performed side by side with
Remicade sourced from the US (infliximab-US)
[5] and the EU (infliximab-EU) [9]. Key
attributes of primary structure,
post-translational modifications, product
purity, charge heterogeneity, and biological
activity were shown to be similar [10]. Based
on the comparative structural and functional
results providing strong support for analytical
similarity, of which only a small subset is
outlined in this nonclinical paper,
PF-06438179 was then evaluated in limited
in vivo nonclinical studies. This study reports
results comparing the structural, functional,
and in vivo nonclinical attributes of
PF-06438179 with those of the reference
product infliximab. Overall, the data
demonstrated analytical and nonclinical
similarity of PF-06438179 to infliximab, and
have supported global clinical trials with
PF-06438179.
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METHODS
Characterization Assays
Peptide Mapping Using Liquid
Chromatography/Mass Spectrometry (LC/MS)
PF-06438179, infliximab-EU, and infliximab-US
samples were denatured in 8-M guanidine HCl
(Sigma-Aldrich), then reduced with
1,4-dithio-DL-threitol (DTT; Sigma-Aldrich) at
40 C for 1 h and alkylated with iodoacetic
acid, sodium salt (Sigma-Aldrich) at room
temperature for 1 h. The reduced/alkylated
samples were desalted using a fast desalting
10/100 GL column (GE Healthcare Life
Sciences) into 50 mM tris buffer pH 8.2, and
digested with trypsin (Roche) at 37 C
overnight. The resulting peptides were
separated by reversed-phase high-performance
liquid chromatography (HPLC) using a C18
column (3.5 lm, 2.1 9 250 mm; Waters
BioSuiteTM) at 35 C with an acetonitrile
gradient containing trifluroacetic acid (Thermo
Scientific). Absorbance was monitored at
214 nm using a Waters-2695 Alliance HPLC
system equipped with an ultraviolet detector
(Waters) and connected to an
ultrahigh-resolution electrospray ionization
quadrupole time-of-flight (UHR ESI-QTOF)
mass spectrometer (Bruker Daltonics maXis)
for identification.
Subunit Analysis Using LC/MS
PF-06438179, infliximab-EU, and infliximab-US
samples were digested at pH 6.6 with the
Ig-degrading enzyme of Streptococcus pyogenes
(IdeS); FabRICATOR IgG protease, Genovis AB.
Following IdeS digestion, denaturation and
disulfide bond reduction was carried out using
guanidine and DTT. The resulting subunits were
injected on a C4 reversed-phase column (Waters
BEH300 C4, 1.7 lm, 2.1 9 100 mm) at a column
temperature of 65 C. Reversed-phase
ultra-HPLC/electrospray ionization quadrupole
time-of-flight (RP-UHPLC ESI-QTOF) mass
spectrometry (MS) was performed on a Waters
H-Class Acquity coupled to an UHR QTOF MS.
Imaged Capillary Isoelectric Focusing
For a quantitative assessment of charge isoforms
by imaged capillary isoelectric (iCE) focusing,
both native and CBP-treated (Sigma-Aldrich)
PF-06438179, infliximab-EU, and infliximab-US
samples were denatured using urea
(Sigma-Aldrich) in methyl cellulose
(ProteinSimple) and 4% Pharmalyte pH 3–10
(GE Healthcare Life Sciences). Prepared samples
were injected onto an FC-coated iCE cartridge
(100 lm ID 9 50 mm; ProteinSimple).
Absorbance was monitored at 280 nm using a
ProteinSimple iCE 280 system. The CBP enzyme
was used to cleave the C-terminal lysine from
the sample by incubating the mixture for 1 h at
25 C.
Size Exclusion HPLC
Native PF-06438179, infliximab-EU, and
infliximab-US samples were fractionated using
a dihydroxypropane bonded silica column
(8 mm 9 300 mm; Waters YMC-Pack Diol-200)
at 30 C and a salt containing mobile phase at
pH 5.0. The analysis was performed using
isocratic flow conditions, and the absorbance
was monitored at 280 nm using a Waters-2695
Alliance HPLC system equipped with an
ultraviolet detector.
Biological Activity
Using an in-house validated assay, a serial
dilution of each PF-06438179, infliximab-EU,
and infliximab-US sample was prepared and
incubated for 35 min at 37 C and 5% carbon
dioxide with recombinant human TNF (R&D
Systems). Then, the content of each incubation
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was added to a 96-well plate containing U937
cells and incubated for 2 h at 37 C and 5%
carbon dioxide. Caspase Glo (Promega Corp.)
reagent was added to the assay, lysing the cells
and producing a luminescent signal
proportional to the apoptotic population of
cells. The luminescent intensity of each well in
the plate was measured using a suitable plate
reader. The dose–response plots were fit with a
4-parameter logistic (4PL) nonlinear regression
model. Relative potency was calculated for test
sample curves deemed parallel to reference
material, using a half-maximal effective
concentration (EC50) ratio in a constrained
4PL fit.
In Vivo Animal Studies
The single- and repeat-dose studies were
conducted in Sprague–Dawley (Crl:CD[SD]) rats
(Charles River Laboratories). All rats were
acclimated to the laboratory environment for a
minimum of 14 (single-dose study) or 13
(repeat-dose study) days prior to initiation of
dosing. The IV route was chosen because it is
consistent with the intended clinical route of
administration and was used during the
nonclinical program of infliximab. Toxicokinetic
(TK) parameters were calculated from individual
animal data using noncompartmental analysis
(Watson LIMS, version 7.4.1; Thermo Inc). TK
parameters includedCmax, timetoCmax, andAUC.
Samples tested below the limit of quantification
(\0.1 lg/mLin100%serum)wereassignedavalue
of 0 lg/mL for the TK calculations.
Single-Dose Study TK and Tolerability Study
Comparing PF-06438179 with Infliximab-EU
in Rats
The objective of this study was to determine the
TK and tolerability of PF-06438179 compared
with infliximab-EU when administered as a
single dose to male rats (aged 9–10 weeks and
weight at dose initiation, 337.9–392.6 g).
PF-06438179 or infliximab-EU was
administered by single IV bolus injection
(volume of 5 mL/kg) to male rats (n = 5/group)
at doses of 10 or 50 mg/kg. A separate group of
five male rats received vehicle #1, and another
group of five male rats received vehicle #2.
Vehicles #1 and #2 consisted of excipients and
buffers identical to those used with
PF-06438179 and infliximab-EU, respectively,
but with no active protein.
Following dose administration, the animals
were retained for an 8-week observation and TK
and anti-drug antibodies (ADA) sampling
period. Clinical signs were assessed daily, and
body weights and quantitative assessment of
food consumption were recorded weekly
through to day 57. For the TK comparison of
PF-06438179 (vehicle #1 and PF-06438179
groups) versus infliximab-EU (vehicle #2 and
infliximab-EU groups), approximately
0.25–0.55 mL of blood was collected from the
jugular vein of each rat prior to dosing, and at
0.5, 4, 8, 24, 48, 96, 168, 336, 672, 1008, and
1344 h following the first and only dose
(administered on day 1). The samples collected
prior to dosing and at 1008 and 1344 h after
dosing were also used for detection of serum
ADA.
Serum PF-06438179 or infliximab-EU
concentrations were determined using a
validated enzyme-linked immunosorbent assay
(ELISA). PF-06438179 or infliximab-EU was
captured using immobilized recombinant
human TNF adsorbed on a microtiter sample
plate. Bound PF-06438179 or infliximab-EU was
detected using a donkey anti-human IgG
antibody conjugated with horseradish
peroxidase and a 3,30,5,50-tetramethylbenzidine
peroxidase substrate solution to generate a
colorimetric readout. Sample concentrations
1968 Adv Ther (2016) 33:1964–1982
were determined by interpolation from a
calibration curve generated using a 4PL
curve-fitting program. Area under the
concentration–time curve, AUC at 1344 h and
extrapolated to infinity (AUC1344 and AUCinf,
respectively), was estimated using the linear
trapezoidal rule.
Serum samples were analyzed for
anti-PF-06438179 or anti-infliximab-EU
antibodies using electro-chemiluminescent
assays validated on the Meso Scale Discovery
(MSD) assay platform. Affinity-purified rabbit
anti-infliximab-EU IgG was the positive control,
and pooled normal SD rat serum was the
negative control. Test samples were first
incubated with biotinylated and ruthenylated
PF-06438179 or infliximab-EU. Aliquots were
added to the wells of a streptavidin-coated
microtiter plate and, following a brief wash,
tripropylamine-containing detection buffer was
added; the resulting chemiluminescent signal
that was proportional to the amount of ADA
present was measured. Samples were tested
using a tiered approach of screening and titer.
The final assessment of induction of an ADA
response for each animal was based on the
comparison of the pre-dose and post-dose
sample results.
Two-Week Toxicity Study of PF-06438179
in Rats
The objective of this study was to determine the
toxicity and TK of PF-06438179 following
administration of 10 or 50 mg/kg (with a
volume of 5 mL/kg) by IV injection once
weekly (days 1, 8, and 15) for 2 weeks to male
and female rats (aged 9 weeks and weight at
dose initiation: male, 289.3–341.7 g; female,
203.7–252.4 g). In the toxicity arm of the
study (n = 10 per sex/group), doses were
administered on days 1, 8, and 15; in the TK
arm (test article-dosed group, n = 4 per sex;
control group, n = 3 per sex), doses were
administered on days 1 and 8. Vehicle
consisted of excipients and buffer, but no
active protein.
Rats were monitored for clinical signs daily,
and for changes in body weight, and food
consumption, weekly, through day 15.
Ophthalmic examinations were performed on
the animals in the toxicity arm prior to the
initiation of dosing (baseline) and on day 13.
Hematology, coagulation, clinical chemistry
parameters, and urinalysis were evaluated on
day 16, just prior to necropsy on this day, which
included full tissue collection, evaluations of
organ weights, and macroscopic and
microscopic observations. Clinical and
anatomic pathology findings were peer
reviewed. For the TK analysis in satellite
animals, approximately 0.30–0.55 mL of blood
was collected from each rat 5 days prior to the
initiation of dosing (day -5) and at 1, 7, 24, 72,
120, and 168 h post-dose on days 1 and 8. In the
vehicle control group, only the 1-, 7-, and 24-h
post-dose samples were analyzed. Serum
samples were analyzed for PF-06438179 using
a validated ELISA assay and analysis methods as
described above. AUC168 was estimated using
the linear trapezoidal rule. For calculations of
day 8 AUC168, the serum concentration of
PF-06438179 at time 0 was set to the day 1,
168-h post-dose concentration.
Compliance with Ethics Guidelines
In vivo animal studies were conducted in
accordance with Good Laboratory Practice for
Nonclinical Laboratory Studies regulations as
set forth in the Code of Federal Regulations (21
CFR Part 58) and in accordance with current
guidelines for animal welfare from the National
Research Council for the Care and Use of
Laboratory Animals. The procedures used in
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these studies were reviewed and approved by




Peptide Mapping Using LC/MS
The chromatographic profiles for PF-06438179,
infliximab-US, and infliximab-EU were
essentially superimposable (Fig. 1). The
identities of corresponding peptides by MS
were consistent between PF-06438179,
infliximab-US, and infliximab-EU, with 100%
of the light chain and 98.7% of the heavy chain
of the amino acid sequence of infliximab
detected. The remaining undetected sequence
corresponded to small peptides (two or fewer
amino acids) that were not retained on the
chromatographic column. For all three
materials, the site of the N-linked
glycosylation was determined to be on the
H26 Fc peptide that contains the NST N-linked
glycosylation consensus sequence. The
predominant N-glycopeptides were G0F and
G1F. For PF-06438179, the predominant
C-terminal form of the heavy chain was
des-lysine; however, for infliximab-US and
infliximab-EU, the predominant C-terminal
form was lysine. Minor modifications such as
heterogeneity of C-terminal lysine are not
expected to be clinically significant [11] and,
therefore, were not considered to impact
similarity [10]. The essentially superimposable
chromatographic profiles of PF-06438179
against the reference products and consistent


























Fig. 1 Peptide map proﬁles (0–130 min) of PF-06438179, inﬂiximab-US, and inﬂiximab-EU. inﬂiximab-US Remicade
sourced from the United States, inﬂiximab-EU Remicade sourced from the European Union
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indicate that the primary sequences of
PF-06438179, infliximab-US, and
infliximab-EU are identical.
Subunit Analysis Using LC/MS
In the subunit analysis, the observed
monoisotopic masses exhibited for the
predominant isoforms of the scFc, Fd0, and
light chain in each material were in excellent
agreement with each other and the respective
theoretical values (Fig. 2). The observed masses
exhibited B1.2 ppm mass measurement errors,
equivalent to a ±0.030 Da tolerance at 25 kDa,
therefore allowing any single amino acid
difference except Leu/Ile to be distinguished at
the subunit level. For each subunit and domain,
there was excellent agreement in the relative
abundance of the individual isotopic species
among each of the three materials, and with the
respective theoretical isotopic distributions,
indicating no subtle structural differences. The
high accuracy of these mass and abundance
measurements indicates that the amino acid
composition of each subunit or domain of the
three infliximab materials is identical and
consistent with the established PF-06438179
sequence. The subunit analysis confirmed in
each material that the scFc domain contained
the expected IgG N-linked glycosylation and
C-terminal heterogeneity with or without
C-terminal lysine. As with the peptide map
analysis, the major N-glycoforms for all three
materials were G0F and G1F. No
post-translational modifications were observed
in Fd’ or in light chain in any of the three
materials.
25188.497 625.13652283.42432
































Fig. 2 Zero-charge mass spectra from liquid
chromatography/mass spectrometry—subunit analysis of
PF-06438179, inﬂiximab-US, and inﬂiximab-EU.
inﬂiximab-US Remicade sourced from the United States,
inﬂiximab-EU Remicade sourced from the European
Union
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iCE Focusing
The iCE profile consistently had three regions:
acidic, main, and basic. The relative content of
basic isoforms of PF-06438179 was less than
that observed for the reference products (Fig. 3).
The basic region primarily contained two peaks,
which correlate to the presence of C-terminal
lysine residues on the heavy chains. The two
basic peaks were suspected to be
mono-C-terminal lysine and di-C-terminal
lysine species. This is consistent with the
heavy chain C-terminal lysine observed by
peptide map and subunit analyses. To confirm
that the difference in the relative proportion of
basic species between PF-06438179 and the
reference products was related solely to
C-terminal lysine, the materials were treated
with carboxypeptidase B (CBP). The
carboxypeptidase cleaves C-terminal lysine
from the three materials, resulting in iCE
profiles representative of the remaining charge
heterogeneity. After treatment with CBP, the
iCE profiles for PF-06438179 and two reference
products were similar (Fig. 4), as were the
relative abundance of acidic, main, and basic
species (Table 1).
Size Exclusion HPLC
The size exclusion HPLC profile had
consistently two peaks: high-molecular mass
species (HMMS) and monomer. Low-molecular
mass peaks were occasionally observed in the
reference product, but levels were just above the
detection limit of the method. The species
under the HMMS peak was confirmed to be
only dimer in all three materials (data not
shown). Analysis of multiple lots of
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Fig. 3 Charge species proﬁles of PF-06438179,
inﬂiximab-US, and inﬂiximab-EU obtained by imaged
capillary isoelectric analysis. inﬂiximab-US Remicade
sourced from the United States, inﬂiximab-EU Remicade
sourced from the European Union
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demonstrated that all three materials were
primarily monomer with similar low levels of
HMMS. Representative profiles are shown in
Fig. 5.
Biological Activity
The functional similarity of PF-06438179,
infliximab-US, and infliximab-EU was assessed
by determining the ability of each to inhibit
TNF-induced apoptosis in the U937 cell line, a
human monocyte cell line that expresses TNF
receptors. In this assay, PF-06438179 binds
specifically to soluble TNF and blocks its
interaction with cell surface TNF receptors on
the U937 cell, thereby inhibiting TNF-induced
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Fig. 4 Charge species proﬁles of carboxypeptidase
B-treated PF-06438179, inﬂiximab-US, and inﬂiximab-EU
obtained by imaged capillary isoelectric analysis.
inﬂiximab-US Remicade sourced from the United States,
inﬂiximab-EU Remicade sourced from the European
Union
Table 1 Quantitation of charge species, obtained by imaged capillary isoelectric analysis of PF-06438179, inﬂiximab-US,
and inﬂiximab-EU before and after treatment with CBP
Before CBP treatment (%) After CBP treatment (%)
Acid Main Basic Acid Main Basic
PF-06438179 27 60 13 32 66 1.7
Inﬂiximab-US 15 38 48 33 66 1.1
Inﬂiximab-EU 18 41 41 33 66 1.0
CBP carboxypeptidase B, inﬂiximab-US Remicade sourced from the United States, inﬂiximab-EU Remicade sourced
from the European Union
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inhibition of cell apoptosis induced by
PF-06438179, infliximab-US, and
infliximab-EU were superimposable (Fig. 6),
demonstrating functional similarity in their
ability to bind TNF. Multiple lots of
PF-06438179 and reference products had
similar relative potencies (data not shown).
In Vivo Rat Studies
Based on the structural and functional similarity
between PF–06438179, infliximab-US, and
infliximab-EU, as demonstrated in the in vitro
characterization assessments, limited in vivo
studies were conducted in Sprague–Dawley rats.
A comparative single-dose TK and tolerability
study with PF-06438179 and one reference
product (infliximab-EU) was conducted
initially. A 2-week IV toxicity study was








































Fig. 5 Size exclusion high-performance liquid
chromatography proﬁles of PF-06438179, inﬂiximab-US,
and inﬂiximab-EU. HMMS High-molecular mass species,
Inﬂiximab-US Remicade sourced from the United States,
inﬂiximab-EU Remicade sourced from the European
Union





























Fig. 6 Inhibition of cell apoptosis: dose–response curves
for PF-06438179, inﬂiximab-US, and inﬂiximab-EU
binding to tumor necrosis factor alpha. inﬂiximab-US
Remicade sourced from the United States, inﬂiximab-EU
Remicade sourced from the European Union
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specific request from a single Regulatory
Authority.
Single-Dose Study TK and Tolerability
of PF-06438179 Versus Infliximab-EU in Male
Rats
Administration of PF-06438179 or
infliximab-EU as a single IV bolus dose to male
rats at 10 or 50 mg/kg was well tolerated, and
the tolerability profiles of PF-06438179 and
infliximab-EU were similar. All rats survived to
the end of the study. There were no clinical
signs attributed to administration of either
PF-06438179 or infliximab-EU, and there were
no PF-06438179- or infliximab-EU-related
changes in body weight, body weight gain, or
food consumption compared with the
respective concurrent vehicle control groups.
No clinical or anatomical pathology parameters
were evaluated in this study.
There were no quantifiable concentrations of
PF-06438179 or infliximab-EU in serum samples
collected from male rats prior to dosing on day
1, or in samples analyzed from vehicle control
groups. Exposure to study drug over the
duration of the study was confirmed in
samples following administration of
PF-06438179 or infliximab-EU. Mean serum
concentration–time profiles of PF-06438179
were similar to infliximab-EU at each dose
following a single IV dose of 10 or 50 mg/kg
(Fig. 7). Systemic exposure, as assessed by Cmax
and area under the concentration–time curve
(AUC) in the PF-06438179 and infliximab-EU
groups, were similar and increased with
increasing dose (Table 1). Mean systemic
exposure ratios Cmax and AUC1344 and AUCinf,
respectively, ranged between 0.88 and 1.16 for
PF-06438179 relative to infliximab-EU (Table 2).
No induction of ADA was detected in rats
receiving either PF-06438179 or infliximab-EU,
nor was there a suggestion of ADA based on
serum concentrations of the PF-06438179 or
infliximab-EU.
Two-Week Toxicity Study of PF-06438179
in Rats
Repeated administration (dosing on days 1, 8,
and 15) of PF-06438179 as an IV bolus injection
to male and female rats at 10 or 50 mg/kg/dose
was well tolerated, and all animals survived to
their scheduled necropsy. There were no
PF-06438179-related clinical signs or effects on
body weight, body weight gain, food
consumption, ophthalmology, coagulation,
clinical chemistry, or urinalysis findings
compared with those parameters for vehicle
control group. PF-06438179-related findings
included higher group mean neutrophil,
monocyte, and large unstained cell counts in
males administered 50 mg/kg, higher group
mean fibrinogen in males and females
administered 50 mg/kg, and lower group mean
platelet counts in females administered 50 mg/
kg (Table 3). These changes were not adverse,
based on their small magnitude and/or the
absence of any correlative clinical observations
or macroscopic or microscopic effects. There


























Fig. 7 Mean (standard deviation) serum concentration
versus time proﬁles of PF-06438179 and inﬂiximab-EU in
rats following a single intravenous injection. inﬂiximab-EU
Remicade sourced from the European Union
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parameters. Compared with control, test
article-related lower platelets (0.88 9 control),
and higher neutrophils (1.82 9 control),
monocytes (1.71 9 control), large unstained
cells (1.87 9 control), and fibrinogen (1.239)
occurred at 50 mg/kg/dose, but these changes
were not adverse based on the magnitude of the
change and lack of any histological correlates.
There were no test article-related differences in
clinical chemistry or urinalysis parameters or
test article-related macroscopic findings.
PF-06438179-related microscopic changes were
limited to minimal to mild sinusoidal cell
hyperplasia in the liver in both males and
females administered 50 mg/kg (Fig. 8;
Table 4). Because of its minimal-to-mild
severity and the lack of other effects on the
liver, this change was not considered adverse.
There were no consistent sex-related
differences in systemic exposure [as assessed
by Cmax and AUC at 168 h (AUC168)]; therefore,
group mean TK parameters are discussed and
presented using combined data from both male
and female rats within each dose group. Mean
systemic exposure increased with increasing
dose in an approximately dose proportional
manner on days 1 and 8 (Table 5). Mean
systemic exposure (AUC168) was higher on day
8 relative to day 1, with day 8:day 1 exposure
ratios of 1.7 and 1.6 at the 10 and 50 mg/kg
doses, respectively. There was no suggestion of
ADA based on consistent serum concentrations
of PF-06438179 throughout the study.
Following once-weekly IV administration of
PF-06438179, 50 mg/kg was identified as the
no-observed adverse-effect level (NOAEL) based
on lack of adverse findings in any in-life or
postmortem evaluations in this 2-week toxicity
study in rats. At this dose, the combined male
and female Cmax was 1360 lg/mL and the
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Fig. 8 Liver from female rats administered vehicle (a), or
50 mg/kg of PF-06438179 (b). Mild sinusoidal cell
hyperplasia in the liver from the PF-06438179-dosed rat
(several sinusoidal cells shown by arrows). A central vein is
in the middle of each photomicrograph. 920 objective
Table 3 Control means and test article-related differences in hematology and coagulation parameters
Parameter Male Female
Dose (mg/kg) Dose (mg/kg)
0 10 50 0 10 50
Platelet counts (9103/lL) – – – 1086.1 – 0.889
Neutrophils (9103/lL) 1.720 – 1.829 – – –
Monocytes (9103/lL) 0.386 – 1.719 – – –
Large unstained cell counts (9103/lL) 0.079 – 1.879 – – –
Fibrinogen (mg/dL) 297.5 – 1.239 254.3 – 1.239
All values are mean control values and ratios relative to control mean
–, no test article-related ﬁnding present
Table 4 Group incidences of test article-related microscopic ﬁndings
Male Female
Dose (mg/kg) Dose (mg/kg)
0 10 50 0 10 50
Livera 10 10 10 10 10 10
Hyperplasia: sinusoidal cell NP NP 9 NP NP 9
Minimal (Grade 1) NP NP 8 NP NP 6
Mild (Grade 2) NP NP 1 NP NP 3
NP ﬁnding not present
a Number examined
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DISCUSSION
In vitro analytical characterization, of which
only a small subset is presented in this study,
demonstrated that the proposed biosimilar,
PF-06438179, is structurally and functionally
similar to its reference products, infliximab-US
and infliximab-EU, and that the reference
products are similar to each other. Peptide
mapping and subunit analyses confirmed that
PF-06438179 has the identical primary structure
as that of the reference product infliximab.
Peptide mapping, subunit analysis, and iCE
focusing confirmed that PF-06438179 has
post-translational modifications similar to
those of the reference products, with the
exception of the levels of C-terminal lysine.
This is a minor difference that is not expected
to be clinically significant because the
C-terminal lysine is rapidly processed in vivo
with a half-life of 62 min [10, 11]. Size exclusion
HPLC confirmed PF-06438179 has a product
profile and a purity similar to those of the
reference products. In the biological activity
assay, PF-06438179 bound TNF, thus inhibiting
TNF binding to its receptors on U937 cells and
subsequently preventing TNF-related cell
apoptosis. PF-06438179 had a similar dose
response curve to that observed with
infliximab-US and infliximab-EU. This
side-by-side analytical characterization
indicates that key structure/function attributes
of reference product infliximabwere successfully
designed into PF-06438179 and provides strong
support that PF-06438179 is analytically similar
to infliximab-US and infliximab-EU. The
analytical characterization also demonstrates
that infliximab-EU is similar to infliximab-US.
Based on this similarity, only a limited
in vivo nonclinical testing program was
considered necessary. This strategy was
consistent with global biosimilar guidance
documents [2, 3, 12, 13] and shaped by
interactions with the EMA (EU), FDA (US), and
Pharmaceuticals and Medical Devices Agency
(Japan). The nonclinical in vivo program
initially conducted consisted of a single-dose
IV TK/tolerability study in male rats to compare
the similarity of PF-06438179 versus
infliximab-EU. The plan to conduct only this
single-dose study in male rats was based on
several factors:









10 1 214 ± 13.8 15,600 ± 882 1560 ± 88.2
8 304 ± 19.6 25,900 ± 1200 2590 ± 120
50 1 993 ± 107 72,300 ± 7420 1450 ± 147
8 1360 ± 111 115,000 ± 12500 2310 ± 252
All values are mean ± standard deviation
AUC168 area under the concentration–time curve from time 0 to 168 h, Cmax maximum drug concentration, Tmax time to
reach maximum serum concentration
a Animals were dosed on days 1 and 8
b Four animals per sex/dose group
c Mean Tmax was observed at 1.0 h in all groups
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1. Infliximab is not pharmacologically active
in typical nonclinical test species [7]. The
only animal species demonstrating
significant pharmacologic activity is
chimpanzees. However, the use of
chimpanzees is not considered ethically
acceptable [14], and thus, a study in
chimpanzees was not appropriate.
2. Conducting toxicity studies in
pharmacologically nonrelevant species is
generally discouraged as they can be
misleading [15], and thus, repeat-dose
toxicity studies in standard nonclinical
species were not considered necessary.
3. No significant infliximab-related findings
were reported in a number of studies with
various species conducted by the
originator, including in chimpanzees as
well as in a variety of
pharmacologically-nonrelevant species.
Thus, conducting toxicity studies with
PF-06438179 (± infliximab-US or
infliximab-EU) would not be expected to
demonstrate any findings, and such
studies were not considered necessary.
4. Although the infliximab-CDR does not
bind TNF from animal species other than
chimpanzees, the neonatal Fc receptor
(FcRn) from animal species including rats
[16] does recognize the Fc fragment of
human immunoglobulin (Ig) G, and thus,
it is possible to characterize
FcRn-mediated/nontarget-related
clearance and TK and assess Fc-related
functionality in animals, including
rodents.
5. Infliximab clearance in humans decreases
with increasing infliximab dose, likely
related to saturation of target-mediated
drug disposition (TMDD), and exposure
appears to be linear at doses of 3–20 mg/kg
[5], which is within the range of the
approved/therapeutic dose of 3–10 mg/kg.
Thus, nontarget-mediated mechanisms
(i.e., FcRn recycling) play a more
significant role in the overall
pharmacokinetics (PK) profile of
infliximab in humans relative to TMDD,
and therefore, PK/TK studies in animal
species that lack TMDD are relevant with
respect to the human PK of infliximab at
these or higher doses.
6. The use of rats (versus mice) enabled serial
blood sampling for the evaluation of
exposure and ADA response in individual
animals over time.
7. Safety and exposure information was
publically available from studies
conducted previously with infliximab in
rats.
8. Only one sex was considered necessary
because no sex differences in TK were
observed with the originator infliximab
in rats [17]. In addition, there were no
major weight-, age-, or sex-related
differences in clearance or volume of
distribution of infliximab in patients [5].
9. The use of only the EU-approved product
(infliximab-EU) as the comparator in the
TK/tolerability study was considered
reasonable because the in vitro assays
demonstrated that infliximab-licensed
products sourced from the US or EU were
similar to each other.
10. Overall, this scientifically based approach
minimized animal use significantly,
compared with a standard toxicology
program.
Like the originator infliximab (Remicade)
studies, there was no PF-06438179- or
infliximab-EU-related toxicity observed during
the single-dose study. The TK profile, systemic
exposures, and ADA response of PF-06438179
were similar to those of infliximab-EU. Based on
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these results, the tolerability, TK, and ADA
responses of PF-06438179 were considered
similar to those of infliximab-EU when
administered as a single IV bolus dose to male
rats at doses of 10 or 50 mg/kg. It should be
noted that the absence or presence of ADA
nonclinically is not predictive of responses in
humans, and because immunogenicity is a key
attribute for establishing biosimilarity between
the proposed biosimilar and the reference
product, it has been/is being monitored in
completed and ongoing clinical studies with
PF 06438179.
The strategy of conducting a single-dose TK
and tolerability study in male rats was successful
in allowing initiation of comparative clinical
(phase I) trials in humans in the US, and is
consistent with recent publications, suggesting
that the requirement for nonclinical in vivo
testing of biosimilars shifts from being a default
requirement to being necessary only under
selected situations where there is residual
doubt regarding similarity that remains
following in vitro testing [13, 18–20].
However, because pharmaceutical companies
are seeking to develop biosimilar drug
products globally, the overall program must
meet the requirements of all countries where
trials and registration are planned. During
additional regulatory interactions, a 2-week
toxicity study with PF-06438179 in both sexes
was requested before clinical trials could
proceed in one country/region. Based on this
request, a 2-week IV toxicity study with
PF-06438179 in male and female rats was
conducted.
In the 2-week toxicity study in rats,
once-weekly IV (bolus) administration of 10 or
50 mg/kg doses of PF-06438179 produced no
adverse findings in any parameters evaluated.
PF-06438179-related microscopic findings were
limited to minimal to mild sinusoidal cell
hyperplasia in the liver in both males and
females administered 50 mg/kg. This finding
was not adverse because of the minimal to mild
severity and lack of other effects on the liver.
The sinusoidal cell hyperplasia observed in this
study was consistent with Kupffer cell
hyperplasia observed in previous studies in rats
following IV administration of Remicade at
either single daily doses C10 mg/kg, or at
seven daily doses C10 mg/kg/day [8], or the
EU-approved biosimilar of Remicade
(Remsima, Celltrion Healthcare Co., Ltd.) at a
dose of up to 40 mg/kg once weekly for 2 weeks
[21]. This finding could have potentially
resulted from the response of a normal rat
reticuloendothelial system to large doses of
chimeric (human–mouse) antibody, a foreign
protein to this test animal [8], and therefore, it
was not considered relevant to humans
administered PF-06438179 or infliximab.
Anti-drug antibodies were not evaluated in the
2-week study because there was no evidence of
an ADA response in the single-dose study, and a
lack of impact on serum concentrations of the
study drug(s) in either study. Other test
article-related differences in platelet counts,
neutrophils, monocytes, large unstained cell
counts, and fibrinogen were nonadverse, based
on their small magnitudes and the lack of any
correlative microscopic findings, such as
inflammation in any organs. Minor
hematologic findings (e.g., increases in
reticulocytes and platelets at 50 mg/kg) have
also been reported following administration of
Remicade or Remsima to rats [17].
CONCLUSIONS
Overall, results with PF-06438179 demonstrate
similarity to infliximab-US and infliximab-EU
based on the in vitro analytical characterization
evaluating protein structure, biological activity,
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and in vivo studies evaluating tolerability,
systemic exposure, and ADA responses. The
test article-related clinical pathology findings
observed with PF-06438179 were considered
nonadverse due to their small magnitude and
lack of any correlative microscopic effect. The
microscopic findings observed in the study with
PF-06438179 were also nonadverse and similar
to microscopic findings reported in rats given
Remicade and Remsima [8, 21]. The nonclinical
in vivo data, when combined with the similarity
demonstrated by the in vitro characterization,
adequately supported the investigation of
PF-06438179 as a potential biosimilar to
Remicade in global comparative clinical trials.
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